AFIB - Acutus Medical sees Q2 revenue above consensus estimate

• Acutus Medical ( NASDAQ: AFIB ) expects Q2 revenues in the range of $4M-$4.1M, compared to consensus estimate of $3.77M .
• The arrhythmia management company generated revenue of $4.7M in the second quarter of 2021
• In other news, Acutus ( AFIB ) appointed David Roman as President and CEO, effective immediately. Roman joined the company as CFO in March 2021 and has also been serving as interim CEO since May 13, 2022. He will continue as CFO until a replacement is found.
• Speaking on the prelim Q2 results, Roman said, "Our deliberate focus on procedure volumes and utilization is gaining momentum, as we achieved another quarter of record procedure volumes with growth on a both a sequential and year-over-year basis. In addition, we are starting to see the benefits of our cost improvement programs with a significant decline in our second quarter 2022 cash burn when compared to the first quarter of 2022."

For further details see: